257 related articles for article (PubMed ID: 12852754)
21. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
[TBL] [Abstract][Full Text] [Related]
22. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
23. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
24. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of unactivated p38 MAP kinase.
Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
[TBL] [Abstract][Full Text] [Related]
26. A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors.
Sperandio da Silva GM; Sant'Anna CM; Barreiro EJ
Bioorg Med Chem; 2004 Jun; 12(12):3159-66. PubMed ID: 15158784
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
[TBL] [Abstract][Full Text] [Related]
28. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
[TBL] [Abstract][Full Text] [Related]
29. 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.
Boehm JC; Smietana JM; Sorenson ME; Garigipati RS; Gallagher TF; Sheldrake PL; Bradbeer J; Badger AM; Laydon JT; Lee JC; Hillegass LM; Griswold DE; Breton JJ; Chabot-Fletcher MC; Adams JL
J Med Chem; 1996 Sep; 39(20):3929-37. PubMed ID: 8831759
[TBL] [Abstract][Full Text] [Related]
30. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
[TBL] [Abstract][Full Text] [Related]
31. Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity.
Laufer S; Koch P
Org Biomol Chem; 2008 Feb; 6(3):437-9. PubMed ID: 18219408
[TBL] [Abstract][Full Text] [Related]
32. Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors.
Odell LR; Nilsson MT; Gising J; Lagerlund O; Muthas D; Nordqvist A; Karlén A; Larhed M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4790-3. PubMed ID: 19560924
[TBL] [Abstract][Full Text] [Related]
33. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
Kwak HJ; Song JS; Heo JY; Yang SD; Nam JY; Cheon HG
J Pharmacol Exp Ther; 2005 Dec; 315(3):1188-95. PubMed ID: 16126838
[TBL] [Abstract][Full Text] [Related]
34. A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors.
Selig R; Goettert M; Schattel V; Schollmeyer D; Albrecht W; Laufer S
J Med Chem; 2012 Oct; 55(19):8429-39. PubMed ID: 22951114
[TBL] [Abstract][Full Text] [Related]
35. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.
Revesz L; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Zimmerlin AG
Bioorg Med Chem Lett; 2000 Jun; 10(11):1261-4. PubMed ID: 10866395
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of imidazole based compounds as cytochrome P-450 inhibitors.
Ahmed S; Smith JH; Nicholls PJ; Whomsley R; Cariuk P
Drug Des Discov; 1995 Aug; 13(1):27-41. PubMed ID: 8882899
[TBL] [Abstract][Full Text] [Related]
39. (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors.
Bamford MJ; Bailey N; Davies S; Dean DK; Francis L; Panchal TA; Parr CA; Sehmi S; Steadman JG; Takle AK; Townsend JT; Wilson DM
Bioorg Med Chem Lett; 2005 Jul; 15(14):3407-11. PubMed ID: 15955699
[TBL] [Abstract][Full Text] [Related]
40. Synthetic methodology utilized to prepare substituted imidazole p38 MAP kinase inhibitors.
Murry JA
Curr Opin Drug Discov Devel; 2003 Nov; 6(6):945-65. PubMed ID: 14758763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]